Anti-Fibrinolytic Drugs - Ghana

Ghana

The projected revenue in the Anti-Fibrinolytic Drugs market for Ghana is expected to reach US$3.30m in 2024.
This revenue is projected to grow at an annual rate of 4.89% from 2024 to 2029, resulting in a market volume of US$4.19m by 2029.
In global comparison, United States is anticipated to generate the highest revenue of US$9,858.00m in 2024.
Ghana's demand for anti-fibrinolytic drugs is rising due to an increase in surgical procedures and a growing aging population.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Fibrinolytic Drugs are used to prevent blood clots from breaking down and are commonly used in surgeries and traumatic injuries. In Ghana, the market for these drugs has been developing in a certain way due to a variety of factors.

Customer preferences: Ghana has a growing population and an increasing number of people are undergoing surgical procedures. As a result, there is a higher demand for Anti-Fibrinolytic Drugs in the country. Additionally, many Ghanaians prefer to use locally made products, which has led to an increase in the production and consumption of these drugs within the country.

Trends in the market: One trend in the Anti-Fibrinolytic Drugs market in Ghana is the increasing use of these drugs in trauma cases. Trauma cases are becoming more common due to an increase in road accidents and other types of injuries. Another trend is the growing use of these drugs in cardiac surgeries, which are also becoming more common as Ghana's healthcare system continues to develop.

Local special circumstances: One local circumstance that has affected the Anti-Fibrinolytic Drugs market in Ghana is the lack of access to healthcare in certain areas of the country. This has led to a higher demand for these drugs in urban areas where healthcare facilities are more readily available. Additionally, the cost of these drugs can be a barrier for some Ghanaians, which has led to the development of cheaper, locally made alternatives.

Underlying macroeconomic factors: Ghana's economy has been growing steadily in recent years, which has led to an increase in the number of surgeries and other medical procedures being performed in the country. Additionally, the government has been investing in the healthcare sector, which has led to improvements in infrastructure and the availability of medical supplies. These factors have contributed to the development of the Anti-Fibrinolytic Drugs market in Ghana.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.